What does this article add
- Our meta-analysis, which is the first to assess the effect of use of
ACEi/ARB in patients with COVID-19, reports that use of ACEi/ARB
statistically significantly reduced the risk of death, with a trend
towards reduction in risk of severe disease and hospitalisation
compared to those who were not on ACEi/ARB.
- Further information from on-going RCTs shall take time to fruition; in
the interim, based on these findings, clinicians can safely continue
to use ACEi/ARB in patients with COVID-19 with comorbidities.